[1]浦丹华综述,葛春晓*审校.GnRHa治疗子宫内膜异位症对卵巢雌激素的影响及对策[J].中国微创外科杂志,2008,08(3):222-224.
点击复制

GnRHa治疗子宫内膜异位症对卵巢雌激素的影响及对策()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
08
期数:
2008年3期
页码:
222-224
栏目:
文献综述
出版日期:
2008-10-25

文章信息/Info

作者:
浦丹华综述; 葛春晓*审校
南京大学医学院附属鼓楼医院妇产科，南京210008
分类号:
R711.71
文献标志码:
A

参考文献/References:

[1]Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann NY Acad Sci, 2003, 997(3): 229-239.
[2]Donnez J. Today’s treatments: medical, surgical and in partnership. Int J Gynaecol Obstet, 1999, 64(Suppl 1):S5-S13.
[3]郎景和,冷金花,赵栋，等.第八届国际子宫内膜异位症学术会议纪要.中华妇产科杂志, 2002, 37(10): 638-640.
[4]Perry CM, Brogden RN. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in benign gynaecological disorders. Drugs, 1996, 51: 319-346.
[5]李书娴. 子宫内膜异位症药物治疗进展. 世界药品信息, 2002, 3(1): 26-27.
[6]Fedele L, Berlanda N. Emerging drugs for endometriosis. Expert Opin Emerg Drugs, 2004, 9(1): 167-177.
[7]Schroder AK, Diedrich K, Ludwig M. Medical management of endometriosis: a systematic review. Drugs, 2004, 7(5): 451-463.
[8]Meldrum DR, Chang RJ, Lu J, et al. Medical oophorectomy using a long acting GnRH agonist: a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab, 1982, 54: 1081-1083.
[9]Meresman GF, Bilotas M, Buquet RA, et al. Gonadotropinreleasing hormone agonist induces apoptosis ad reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. Fertil Steril, 2003, 80: 702-707.
[10]Hara R, Araki H, Kusaka M, et al. Suppression of a pituitaryovarianaxis by chronic oral administration of a novel nonpeptide gonadotropinreleasling hormone antagonist, TAK013, in cynomolgus monkeys. Clin Endocrinol Metab, 2003, 88(4):1697-1704.
[11]曹泽毅, 主编. 中华妇产科学. 第1版. 北京: 人民卫生出版社, 1999. 39.
[12]于传鑫, 李诵絃, 主编. 实用妇科内分泌学. 第2版. 上海: 复旦大学出版社, 2004. 241.
[13]Sagsveen M, Farmer J, Prentice A. Gonadotrophinreleasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev, 2003, (4): CD001297.
[14]Matsuo H. Prediction of the change in bone mineral density induced by gonadotropinreleasing hormone agonist treatment for endometriosis. Fertil Steril, 2004, 81(1): 149-153.
[15]Niki B, Sean D. The effects of a 3month depot preparation of leuprorelin acetate on pain symptoms, bone mineral density and hormone levels in women with endometriosispreliminary data analysis. Gynecol Surg, 2004, 1: 107-109.
[16]Prentice A, Deary AJ, GoldbeckWood S, et al. Gonadotrophinreleasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev,1999，(2):CD000346.
[17]邱晓燕, 酆豫增, 陈淑影. 丙氨瑞林和达那唑治疗子宫内膜异位症对照研究. 上海医科大学学报, 1999, 26: 39-41.
[18]Okada H, Heya T, Ogawa YE, et al. Sustained pharmacologicol activities in rats following single and repeated administration of one month injectable microsphere of leuprolide acetate. Pharm Res, 1991, 8: 584.
[19]赵瑞钦, 周美华, 瞿文,等. 丙氨瑞林缓释微球注射剂对大鼠异位子宫内膜抑制作用. 药学学报, 1999, 34(8): 565-568.
[20]吴红, 邵敬於, 林敏. 长效醋酸亮丙瑞林缓释微球注射剂治疗性激素依赖性疾病合并不孕症. 中国新药与临床杂志, 2006, 25(12): 939-941.
[21]Matteo M, Caroppo E, Gliozheni O, et al. Pituitary desensitization for eight weeks after the administration of two distinct gonadotrophinreleasing hormone agonists.Eur J Obstet Gynecol Reprod Biol,2006,126(1):77-80.
[22]Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and longacting gonadotropinreleasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. Clin Endocrinol Metab, 1992, 75(2): 558-563.
[23]Barbieri RL. Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J Reprod Med, 1998, 43(3): 287-292.
[24]Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gymaecol, 1992, 166(2): 740.
[25]DiVasta A, Laufer M, Gordon C. Preservation of bone mineral density in adolescents treated with GnRH agonists and addback therapy for endometriosis. North American Society for Pediatric and Adolescent Gynecology Annual Meeting. Orlando, Florida. 2006. 136-137.
[26]Zupi E, Marconi D, Sbracia M. Addback therapy in the treatment of endometriosisassociated pain. Fertil Steril, 2004, 82(5):1303-1308.
[27]许雪燕, 张友忠，汪倩. GnRHa与小剂量利维爱反加疗法在治疗子宫内膜异位症中的应用. 现代妇产科进展, 2003, 12(2): 120-123.
[28]张绍芬, 陈珣, 张剑峰,等. 促性腺激素释放激素激动剂与口服避孕药联合治疗重度子宫内膜异位性疾病的研究. 中国实用妇科与产科杂志, 2006, 22(12): 912-914.
[29]张翔. GnRHa治疗子宫内膜异位症的研究进展. 国外医学·妇产科学分册, 2005, 32(4): 243-246.
[30]Olive DL. The role of addback therapy in the United States. Drugs Today (Barc), 2005, 41(A): 23-26.
[31]Tahara M, Matsuoka T, Yokoi T, et al. Treatment of endometriosis with a decreasing dosage of a gonadotropin releasing hormone agonist(nafarelin): a pilot study with lowdose agonist terapy(“drawback”therapy). Fertil Steril, 2000, 73(4): 800-804.
[32]Uemura T, Shirasu K, Katagiri N, et al. Lowdose GnRH agonist therapy for the management of endometriosis. J Obstet Gynaecol Res, 1999, 25(5): 295-301.
[33]刘德艳, 顾美皎, 舒家振,等. 促性腺激素释放激素激动剂延长用药间隔治疗子宫内膜异位症和子宫腺肌病的疗效观察. 中华妇产科杂志, 2006, 41(10): 656-659.

备注/Memo

备注/Memo:
*通讯作者
更新日期/Last Update: 2013-10-22